LAURIE SEWELL-MULLER: Open Payments
NPI 1518685254 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,131 in 134 payments from 20 companies in 2025. Trend: 2023 $417 · 2024 $2,059 · 2025 $2,131
Food & beverage: $2,131
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $303 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $297 |
| Axsome Therapeutics, Inc. | 18 | $262 |
| Vanda Pharmaceuticals Inc. | 12 | $203 |
| HARMONY BIOSCIENCES LLC | 12 | $178 |
| E.R. Squibb & Sons, L.L.C. | 8 | $152 |
| Alkermes, Inc. | 11 | $151 |
| Lundbeck LLC | 6 | $109 |
| Otsuka America Pharmaceutical, Inc. | 5 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $98 |
Products named: CAPLYTA, Auvelity, WAKIX, REXULTI, COBENFY, VRAYLAR, QULIPTA, FANAPT.
Industry payments across NE — which companies pay providers there.
